Investor Presentation

Date: November 02, 2026 Ref. No.: KDL/SE/064/2026-27 To, To, BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Exchange Plaza, Plot No. C-1, Block G, 25th Floor, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (East) Dalal Street, Mumbai- 400001 Mumbai – 400051 Scrip Code: 543328 NSE Symbol: KRSNAA Dear Sir/Madam, Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for Investor Presentation. Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a copy of the presentation for the Investors/Analysts on Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2026. Request you to take the same on your records. Thanking you, Yours sincerely, For Krsnaa Diagnostics Limited Sujoy Sudipta Bose Company Secretary & Compliance Officer Encl: as above Q2 FY2026-27 Result Presentation One of INDIA’S LARGEST Integrated Diagnostic Service Provider Disclaimer This presentation contains statements that are “forward-looking statements”, including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements pertaining to Krsnaa Diagnostics’ future business developments and economic performance. While these forward-looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macroeconomic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Krsnaa Diagnostics undertakes no obligation to publicly revise any forward-looking statements to reflect future/ likely events or circumstances. © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 251 Mn+ 196 81 8,400+ Tests in CT/ MRI Centres Million+ 35% in 5 Years Patient Touch Points Patients Served YoY Retail Revenue In Last 5 Years Growth Districts 75% States/UT Pathology Labs Presence Centers Cover Rural Presence in India PAN India Areas of India One of India’s largest NABH-accredited Krsnaa Diagnostics is one of the fastest tele-radiology reporting hubs with growing and the largest Integrated inherent capability & capacity to diagnostic service provider which The workforce comprises 350+ Provides quality care, accessibility, process X-rays, CT scans, and MRI scans, includes radiology, pathology and tele- radiologists, 100+ pathologists, and accuracy at affordable rates serving patients at the remotest radiology and 3,000+ qualified across various segments with a locations in real-time. professionals, including clinicians, focus on the Public-Private technicians and operators Partnership model © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 Company Evolution: Our Success & Scale Story A proven trajectory of PPP leadership, nationwide expansion, and diagnostic quality excellence. 2011-13 2013-18 2021-22 2022-23 INCEPTION PPP ENTRY IPO & EXPANSION QUALITY FIRST Kick Start with 2 Radiology Centers 1st PPP Contract with 12 CT Centers in Successful IPO Listing & Expansion to 1st in India to get NABH Teleradiology HP 14 States Accreditation 2023-24 2024-25 2025-26 2026-27 MEGA CT /MRI PROJECTS FOREAY IN RETAIL PATHOLOGY MEGA PPP SPECIALIZED CARE Awarded Largest Integrated Pathology PPP Awarded Largest CT/MRI Projects in Retail Diagnostics Market Entry in Entry into Specialized PET CT project across Rajasthan state. Strategic MH & MP. Maharashtra, Assam, Punjab and Diagnostics in PPP investment in Apulki – Oncology & Cardiac Orissa specialized diagnostics 200+ 19 States 75 NABH + 57 NABL PET CT CT & MRI Centers Pan-India Footprint Highest accredited centers in India Specialized Care Frontier Q2 FY27 Financial Performance Particulars Q2 FY27 Q2 FY26 YoY % Particulars Q2 FY27 Q2 FY26 YoY % Revenue 2,710 2,060 32% No. of Test Performed 30.3 16.4 85% (Mn) EBIDTA 719 602 20% No. of Patient Served 7.3 5.4 35% (Mn) EBIDTA Margin 27% 29% 2% NABL Accreditation 57 57 (Pathology lab) PAT 246 239 3% NABH Accreditation 75 36 108% PAT Margin 9% 12% 3% (Radiology Centre) The moderation in margins is primarily a function of the upfront fixed cost base of Rajasthan laboratories, equipment, manpower and logistics being carried ahead of full utilisation. Note: 1. Financial results of the Company are best monitored on an annual basis, as there is a certain level of cyclicity in business, and specific quarter performance may be impacted by specific events in that quarter 2. EBIDTA is excluding CSR & ESOP 3. INR in mn except NABL & NABH © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 5 Retail Business Highlights Revenue Retail Revenue Retail Revenue Patient Count Test Volume Per Patient Contribution to (INR Mn) (Mn) (Mn) (INR) Group Revenue 235 0.26 0.69 967 904 0.47 Q2 FY26 Q2 FY27 174 0.18 8% 9% Q2 FY26 Q2 FY27 Q2 FY26 Q2 FY27 Q2 FY26 Q2 FY27 Q2 FY26 Q2 FY27 Up 35% YoY Up 45% YoY Up 48% YoY Optimizing Affordability Stronger revenues driven by higher Higher test volumes reflect deeper More patients trusting our services Focused on affordability while RPL Krsnaa patient engagement and expanded penetration and improved every day maintaining quality and trust reach accessibility Expanding Deepening Enhancing Driving One Year. Multiple Milestones. Footprint Patient Trust Accessibility Sustainable Growth More patients. Better experience. Stronger foundation Wider reach across Accelerating Retail Excellence. More relationships. Easier access. for long-term value new geographies Stronger trust. Greater convenience. creation. Growth Drivers 1.Rising Burden of Chronic & Non- 1.Unorganized-to-Organized Transition Communicable Diseases (NCDs) 2. Tier-2 / Tier-3 Geographical 2. Shift to Preventive & Wellness Expansion Health 3. Aging Population & Higher Life Expectancy Industry Structural & Consolidation Demographic & Organized Drivers Shift Technology & Ecosystem & Portfolio Policy Push Premiumization 1. Expanding Health Insurance 1. Advanced & Specialized Testing Penetration 2. Digital Access & Home Sample 2. Increasing Test Density per Collection Encounter 3. AI & Operational Automation © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 7 Financial Performance Consolidated Financial Performance In INR Mn Particulars Q2 FY 27 Q2 FY 26 Q1 FY 27 H1 FY 27 H1 FY 26 Amount % Amount % Amount % Amount % Amount % Revenue from operations 2,710 2,060 2,355 5,065 3,990 Expenses Cost of Material Consumed 558 21% 481 23% 502 21% 1,060 21% 955 24% Employee benefits expense 367 14% 348 17% 357 15% 724 14% 698 18% Fees Channel Partners and 507 19% 170 8% 406 17% 913 18% 324 8% Collection Centres Other expenses 558 21% 459 22% 502 21% 1,061 21% 887 22% Total Expenses 1990 73% 1,458 71% 1,767 75% 3,758 74% 2,864 72% EBITDA Before CSR & ESOP 719 27% 602 29% 588 25% 1,307 26% 1,126 28% CSR and ESOP 8 0.3% 10 1% 8 0.3% 16 0.3% 20 0.5% EBITDA 711 26% 592 29% 580 25% 1,291 25% 1,106 28% Less: Finance costs 155 6% 82 4% 148 6% 303 6% 145 4% Less: Depreciation 291 11% 236 11% 280 12% 570 11% 452 11% Add: Other income 62 2% 42 2% 72 3% 134 3% 82 2% PBT 328 12% 316 15% 224 10% 552 11% 591 15% Tax 82 3% 77 4% 59 2% 141 3% 146 4% PAT 246 9% 239 12% 166 7% 411 8% 445 11% © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 9 Consolidated Financial Performance (INR In Mn) Liabilities Sep 30, 2026 Mar 31, 2026 Assets Sep 30, 2026 Mar 31, 2026 Equity Non-current assets Equity shar [Showing first 8,000 characters — download PDF for full document]